8-K: KindlyMD Reports Second Quarter 2024 Results, Highlights Insurance Reimbursement Growth

KindlyMD announced its second quarter 2024 financial results, showcasing a significant 163.7% sequential increase in insurance reimbursements, while also reporting a decrease in overall revenue.

Summary

• KindlyMD reported its financial results for the second quarter of 2024, ending June 30th.
• The company saw a 163.7% increase in reimbursements from insurance payors compared to the previous quarter, reaching $91,553.
• Total reimbursements for the first half of 2024 were $126,325, compared to $0 in the same period of 2023.
• However, total revenue decreased by 34.8% to $639,057 compared to $979,538 in the same quarter of the previous year.
• This revenue decrease is attributed to a shift from cash-pay patient services to insurance billing.
• Operating expenses increased by 6.0% to $1,676,250.
• The net loss per share decreased to $(0.26) from $(0.13) in the same quarter of the previous year.
• The company completed its IPO in June 2024, raising net proceeds of $6.02 million.
• As of June 30, 2024, KindlyMD had $4.74 million in cash and cash equivalents and $4.11 million in total working capital.
• KindlyMD now provides nearly 80% statewide comprehensive insurance coverage in Utah.

Sentiment

Score: 5

Explanation: The document presents mixed results. While the increase in insurance reimbursements is positive, the decrease in overall revenue and increased operating expenses temper the positive aspects. The company's future outlook is cautiously optimistic, but there are risks associated with its growth strategy.

Positives

• Insurance reimbursements increased significantly by 163.7% sequentially in Q2 2024.
• The company has secured contracts with major insurance providers, covering nearly 80% of Utah.
• KindlyMD is the first alternative medical treatment company in Utah to contract with top insurance payors.
• The IPO in June 2024 provided $6.02 million in net proceeds, strengthening the company's financial position.
• The company has a strong cash position with $4.74 million in cash and cash equivalents.
• KindlyMD is actively pursuing growth through acquisitions of clinics.

Negatives

• Total revenue decreased by 34.8% in Q2 2024 compared to the same period last year.
• Operating expenses increased by 6.0% in Q2 2024.
• The net loss per share decreased to $(0.26) in Q2 2024 compared to $(0.13) in Q2 2023.
• The decrease in revenue is primarily attributed to a decrease in cash-pay patient care services.

Risks

• The company's shift from cash-pay to insurance billing may impact revenue in the short term.
• The company's growth strategy relies on successful acquisitions, which may not materialize.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's operating expenses have increased, which could impact profitability.

Future Outlook

KindlyMD intends to continue growing its insurance reimbursement revenue, acquire new patients, and expand its footprint through acquisitions. The company believes it has adequate liquidity to meet its obligations for at least the next 12 months and to implement its strategic plans.

Management Comments

• Tim Pickett, PA-C, KindlyMD Founder and CEO, stated, 'During the second quarter we successfully closed on our IPO for gross proceeds of approximately $6 million.'
• Tim Pickett also noted, 'While from a total revenue perspective during the quarter we did not yet yield the return on investment from the additional working capital we received, we are very pleased with the 163.7% sequential growth in reimbursement from insurance payors.'
• Management is focused on optimizing revenue by increasing sales, acquiring additional clinics, improving margins, and controlling operating expenses.

Industry Context

The announcement highlights KindlyMD's position as a leader in the alternative medical treatment market in Utah, particularly in securing contracts with major insurance providers. The company's focus on integrating traditional and alternative therapies aligns with a growing trend in healthcare towards holistic and patient-centered care. The company is also leveraging the growing acceptance of medical cannabis.

Comparison to Industry Standards

• The 163.7% sequential increase in insurance reimbursements is a strong indicator of growth in this area, however, the decrease in overall revenue is a concern.
• Compared to other healthcare companies, KindlyMD's focus on alternative therapies and medical cannabis is a differentiator.
• The company's ability to secure contracts with major insurance providers is a positive sign, as this is a key factor for revenue growth in the healthcare industry.
• The company's IPO and subsequent cash position are positive, but the company needs to demonstrate that it can convert this into revenue growth and profitability.
• Companies such as Curaleaf, with whom KindlyMD has partnered, are also focused on the medical cannabis market, but KindlyMD is unique in its integration of traditional and alternative therapies.

Stakeholder Impact

• Shareholders will be interested in the company's revenue growth and profitability.
• Employees may be impacted by the company's growth strategy and potential acquisitions.
• Customers will benefit from the company's expanded insurance coverage and services.
• Suppliers may see increased business opportunities as the company grows.
• Creditors will be interested in the company's financial stability and ability to meet its obligations.

Next Steps

• KindlyMD will continue to focus on growing its insurance reimbursement revenue.
• The company will pursue acquisitions of clinics in Utah to expand its footprint.
• KindlyMD will continue to invest in acquiring new patients.
• The company will update shareholders on its progress in the near future.

Key Dates

Keywords

insurance reimbursements, financial results, IPO, healthcare, alternative medicine, acquisitions, Utah, medical cannabis, patient care, revenue